Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

1343550

USP

Iodixanol Related Compound D

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

Iopentol, 5-[Acetyl(2-hydroxy-3-methylpropyl)amino]-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C20H28I3N3O9
Numero CAS:
89797-00-2
Peso molecolare:
835.16
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

iodixanol

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

InChI

1S/C20H28I3N3O9/c1-9(29)26(5-12(32)8-35-2)18-16(22)13(19(33)24-3-10(30)6-27)15(21)14(17(18)23)20(34)25-4-11(31)7-28/h10-12,27-28,30-32H,3-8H2,1-2H3,(H,24,33)(H,25,34)
IUNJANQVIJDFTQ-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Iodixanol Related Compound D USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Iodixanol Injection
  • Iodixanol

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0001294

Iodixanol, European Pharmacopoeia (EP) Reference Standard

Y0001292

Iodixanol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001291

Iodixanol impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001293

Iodixanol impurity H, European Pharmacopoeia (EP) Reference Standard

1343517

Iodixanol, United States Pharmacopeia (USP) Reference Standard

1343540

Iodixanol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1343561

Iodixanol Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR3015

Iodixanol, pharmaceutical secondary standard, certified reference material

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Nikolaos L Kelekis et al.
Clinical imaging, 28(2), 124-127 (2004-03-31)
Confluent hepatic fibrosis (CHF) is usually a feature of advanced cirrhosis, while occurrence in early stage compensated cirrhosis is uncommon. We report the imaging findings of masslike CHF in a patient with previously unsuspected compensated alcoholic cirrhosis. The combination of
Markus Selzner et al.
Annals of surgery, 240(6), 1027-1034 (2004-12-01)
To compare the diagnostic value of contrast-enhanced CT (ceCT) and 2-[18-F]-fluoro-2-deoxyglucose-PET/CT in patients with metastatic colorectal cancer to the liver. Despite preoperative evaluation with ceCT, the tumor load in patients with metastatic colorectal cancer to the liver is often underestimated.
Amina Abdelmoumene et al.
European radiology, 15(9), 1881-1887 (2005-05-04)
This study compared different acquisition protocols performance to detect small liver metastases (<2 cm). Thirty consecutive patients with histologically proven hepatic metastases were explored by MDCT at the liver equilibrium phase by four successive acquisitions. We compared the following protocols
S G Spitzer et al.
Acta radiologica (Stockholm, Sweden : 1987), 43(6), 617-622 (2002-12-18)
To investigate the influence of two non-ionic radiographic contrast media with different osmolality on thrombocytic function and the plasmatic coagulation system. The study was carried out as a randomised, prospective, comparative study with two contrast media in a heart catheter
Severe Stevens-Johnson syndrome induced by contrast medium iopentol (Imagopaque).
E Laffitte et al.
The British journal of dermatology, 150(2), 376-378 (2004-03-05)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.